JPRN-jRCT2051210038进行中（未招募）1 期
ONO-7913: ONO-7913 Phase 1 Study; An open-label, uncontrolled study of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
Hirashima Yoshinori0 个研究点目标入组 60 人开始时间: 2021年6月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Unresectable advanced or recurrent colorectal cancer
- •2. Life expectancy of at least 3 months
- •3. Patients with ECOG performance status 0 or 1
排除标准
- •1. Patients with severe complication
- •2. Patients with multiple primary cancers
研究者
相似试验
招募中
1 期
ONO-7914-01:Phase I study of ONO-7914 alone and in combination with ONO-4538 in patients with solid tumorsJPRN-jRCT2031210530Hirashima Yoshinori204
进行中（未招募）
1 期
ONO-7475-03 : ONO-7475 Phase 1 StudyEGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiationJPRN-jRCT2051210045Osawa Masahiro75
进行中（未招募）
1 期
ONO-7119-01:Phase I study of ONO-7119 alone and in combination with ONO-4538 in patients with solid tumorsJPRN-jRCT2031210373Hirashima Yoshinori74
进行中（未招募）
1 期
ONO-7913-02 : ONO-7913 Phase 1 StudyJPRN-jRCT2031210139Osawa Masahiro12
招募中
1 期
ONO-4578-02:ONO-4578 Phase 1 Studynresectable colorectal cancerJPRN-jRCT2031200215Hirashima Yoshinori36